Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies
Abstract
:Simple Summary
Abstract
1. Introduction
2. Early-Stage Cervical Cancer
2.1. Upfront Surgical Treatment
2.2. Indications for Adjuvant (Chemo)radiotherapy
2.3. Upfront Radiotherapy to Avoid Cumulative Morbidities
2.4. Place of Image-Guided Intensity-Modulated Radiotherapy (IG-IMRT)
2.5. Neoadjuvant Brachytherapy
2.6. Challenging Situations
2.7. Sequential Adjuvant Chemoradiation
3. Locally Advanced Cervical Cancer
3.1. Standard of Care
3.2. Completion/Salvage Hysterectomy
3.3. Neoadjuvant Chemotherapy
3.4. Adjuvant Chemotherapy
3.5. Adjuvant Immunotherapy
3.6. Perspectives
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem; World Health Organization: Geneva, Switzerland, 2020.
- Chargari, C.; Arbyn, M.; Leary, A.; Abu-Rustum, N.R.; Basu, P.; Bray, F.; Chopra, S.; Nout, R.; Tanderup, K.; Viswanathan, A.N.; et al. Increasing global accessibility to high-level treatments for cervical cancers. Gynecol. Oncol. 2022, 164, 231–241. [Google Scholar] [CrossRef] [PubMed]
- Grigsby, P.W.; Siegel, B.A.; Dehdashti, F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J. Clin. Oncol. 2001, 19, 3745–3749. [Google Scholar] [CrossRef]
- Choi, H.J.; Ju, W.; Myung, S.K.; Kim, Y. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: Meta-analysis. Cancer Sci. 2010, 101, 1471–1479. [Google Scholar] [CrossRef]
- Reinhardt, M.J.; Ehritt-Braun, C.; Vogelgesang, D.; Ihling, C.; Hogerle, S.; Mix, M.; Moser, E.; Krause, T.M. Metastatic lymph nodes in patients with cervical cancer: Detection with MR imaging and FDG PET. Radiology 2001, 218, 776–782. [Google Scholar] [CrossRef]
- Mathevet, P.; Lécuru, F.; Uzan, C.; Boutitie, F.; Magaud, L.; Guyon, F.; Querleu, D.; Fourchotte, V.; Baron, M.; Bats, A.-S.; et al. Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2). Eur. J. Cancer 2021, 148, 307–315. [Google Scholar] [CrossRef] [PubMed]
- Bhatla, N.; Berek, J.S.; Cuello Fredes, M.; Denny, L.A.; Grenman, S.; Karunaratne, K.; Kehoe, S.T.; Konishi, I.; Olawaiye, A.B.; Prat, J.; et al. Revised FIGO staging for carcinoma of the cervix uteri. Int. J. Gynecol. Obstet. 2019, 145, 129–135. [Google Scholar] [CrossRef]
- Marth, C.; Landoni, F.; Mahner, S.; McCormack, M.; Gonzalez-Martin, A.; Colombo, N.; on behalf of the ESMO Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017, 28, 72–83. [Google Scholar] [CrossRef]
- Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: Individual patient data meta-analysis. Cochrane Database Syst. Rev. 2010, 1, CD008285. [Google Scholar]
- Amant, F.; Berveiller, P.; Boere, I.; Cardonick, E.; Fruscio, R.; Fumagalli, M.; Halaska, M.; Hasenburg, A.; Johansson, A.; Lambertini, M.; et al. Gynecologic cancers in pregnancy: Guidelines based on a third international consensus meeting. Ann. Oncol. 2019, 30, 1601–1612. [Google Scholar] [CrossRef] [Green Version]
- Ph, M.; Maulard, A.; Scherier, S.; Sanson, C.; Zarokian, J.; Zaccarini, F.; Espenel, S.; Pautier, P.; Leary, A.; Genestie, C.; et al. Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review. Gynecol. Oncol. 2022, 165, 169–183. [Google Scholar] [PubMed]
- Lee, Y.-N.; Wang, K.L.; Lin, M.-H.; Liu, C.-H.; Wang, K.-G.; Lan, C.-C.; Chuang, J.-T.; Chen, A.-C.; Wu, C.-C. Radical hysterectomy with pelvic lymph node dissection for treatment of cervical cancer: A clinical review of 954 cases. Gynecol. Oncol. 1989, 32, 135–142. [Google Scholar] [CrossRef]
- Cibula, D.; Pötter, R.; Planchamp, F.; Avall-Lundqvist, E.; Fischerova, D.; Meder, C.H.; Köhler, C.; Landoni, F.; Lax, S.; Lindegaard, J.C.; et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. Int. J. Gynecol. Cancer 2018, 28, 641–655. [Google Scholar] [CrossRef] [PubMed]
- Sartori, E.; Tisi, G.; Chiudinelli, F.; La Face, B.; Franzini, R.; Pecorelli, S. Early stage cervical cancer: Adjuvant treatment in negative lymph node cases. Gynecol. Oncol. 2007, 107 (Suppl. 1), S170–S174. [Google Scholar] [CrossRef] [PubMed]
- Querleu, D.; Leblanc, E.; Cartron, G.; Narducci, F.; Ferron, G.; Martel, P. Audit of preoperative and early complications of laparoscopic lymph node dissection in 1000 gynecologic cancer patients. Am. J. Obstet. Gynecol. 2006, 195, 1287–1292. [Google Scholar] [CrossRef]
- Achouri, A.; Huchon, C.; Bats, A.; Bensaid, C.; Nos, C.; Lécuru, F. Complications of lymphadenectomy for gynecologic cancer. Eur. J. Surg. Oncol. 2013, 39, 81–86. [Google Scholar] [CrossRef] [PubMed]
- Ramirez, P.T.; Frumovitz, M.; Pareja, R.; Lopez, A.; Vieira, M.; Ribeiro, M.; Buda, A.; Yan, X.; Shuzhong, Y.; Chetty, N.; et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N. Engl. J. Med. 2018, 379, 1895–1904. [Google Scholar] [CrossRef]
- Chiva, L.; Zanagnolo, V.; Querleu, D.; Martin-Calvo, N.; Arévalo-Serrano, J.; Căpîlna, M.E.; Fagotti, A.; Kucukmetin, A.; Mom, C.; Chakalova, G.; et al. SUCCOR study: An international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer. Int. J. Gynecol. Cancer 2020, 30, 1269–1277. [Google Scholar] [CrossRef]
- Cibula, D.; Abu-Rustum, N.R.; Fischerova, D.; Pather, S.; Lavigne, K.; Slama, J.; Alektiar, K.; Ming-Yin, L.; Kocian, R.; Germanova, A.; et al. Surgical treatment of “intermediate risk” lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature. Gynecol. Oncol. 2018, 151, 438–443. [Google Scholar] [CrossRef]
- Allam, M.; Feely, C.; Millan, D.; Nevin, J.; Davis, J.; Siddiqui, N. Depth of cervical stromal invasion as a prognostic factor after radical surgery for early stage cervical cancer. Gynecol. Oncol. 2004, 93, 637–641. [Google Scholar] [CrossRef]
- Park, J.-Y.; Kim, D.-Y.; Kim, J.-H.; Kim, Y.-M.; Nam, J.-H. Outcomes after radical hysterectomy according to tumor size divided by 2-cm interval in patients with early cervical cancer. Ann. Oncol. 2011, 22, 59–67. [Google Scholar] [CrossRef] [PubMed]
- Horn, L.-C.; Bilek, K.; Fischer, U.; Einenkel, J.; Hentschel, B. A cut-off value of 2cm in tumor size is of prognostic value in surgically treated FIGO stage IB cervical cancer. Gynecol. Oncol. 2014, 134, 42–46. [Google Scholar] [CrossRef] [PubMed]
- Peters, W.A., 3rd; Liu, P.Y.; Barrett, R.J., 2nd; Stock, R.J.; Monk, B.J.; Berek, J.S.; Souhami, L.; Grigsby, P.; Gordon, W., Jr.; Alberts, D.S. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 2000, 18, 1606–1613. [Google Scholar] [CrossRef] [PubMed]
- Levinson, K.; Beavis, A.L.; Purdy, C.; Rositch, A.F.; Viswanathan, A.; Wolfson, A.H.; Kelly, M.G.; Tewari, K.S.; McNally, L.; Guntupalli, S.R.; et al. Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. Gynecol. Oncol. 2021, 162, 532–538. [Google Scholar] [CrossRef]
- Rotman, M.; Sedlis, A.; Piedmonte, M.R.; Bundy, B.; Lentz, S.S.; Muderspach, L.I.; Zaino, R.J. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: Follow-up of a gynecologic oncology group study. Int. J. Radiat. Oncol. 2006, 65, 169–176. [Google Scholar] [CrossRef]
- Sedlis, A.; Bundy, B.N.; Rotman, M.Z.; Lentz, S.S.; Muderspach, L.I.; Zaino, R.J. A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol. Oncol. 1999, 73, 177–183. [Google Scholar] [CrossRef]
- Gultekin, M.; Esen, C.S.B.; Balci, B.; Alanyali, S.; Yildirim, B.A.; Guler, O.C.; Sari, S.Y.; Ergen, S.A.; Sahinler, I.; Cetin, I.A.; et al. Role of vaginal brachytherapy boost following adjuvant external beam radiotherapy in cervical cancer: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-002). Int. J. Gynecol. Cancer 2021, 31, 185–193. [Google Scholar] [CrossRef]
- Contreras, J.; Srivastava, A.; Chundury, A.; Schwarz, J.K.; Markovina, S.; Thaker, P.H.; Massad, L.S.; Mutch, D.G.; Powell, M.A.; Grigsby, P.W.; et al. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer. Int. J. Gynecol. Cancer 2020, 30, 1157–1161. [Google Scholar] [CrossRef]
- Bronsart, E.; Petit, C.; Gouy, S.; Bockel, S.; Espenel, S.; Kumar, T.; Fumagalli, I.; Maulard, A.; El Ayachy, R.; Genestie, C.; et al. Evaluation of adjuvant vaginal vault brachytherapy in early stage cervical cancer patients. Cancer Radiother. 2020, 24, 860–865. [Google Scholar] [CrossRef]
- Landoni, F.; Maneo, A.; Colombo, A.; Placa, F.; Milani, R.; Perego, P.; Favini, G.; Ferri, L.; Mangioni, C. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997, 350, 535–540. [Google Scholar] [CrossRef]
- Landoni, F.; Colombo, A.; Milani, R.; Placa, F.; Zanagnolo, V.; Mangioni, C. Randomized study between radical surgery and radiotherapy for the treatment of stage IB–IIA cervical cancer: 20-year update. J. Gynecol. Oncol. 2017, 28, e34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nout, R.A.; Putter, H.; Jürgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.; van der Steen-Banasik, E.M.; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Nijman, H.W.; et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur. J. Cancer 2012, 48, 1638–1648. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nout, R.A.; Putter, H.; Jürgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Van Der Steen-Banasik, E.M.; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Van Bunningen, B.N.F.M.; et al. Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial. J. Clin. Oncol. 2009, 27, 3547–3556. [Google Scholar] [CrossRef] [PubMed]
- Nout, R.A.; Smit, V.T.; Putter, H.; Jürgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.; van der Steen-Banasik, E.; Mens, J.; Slot, A.; Kroese, M.S.; et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial. Lancet 2010, 375, 816–823. [Google Scholar] [CrossRef]
- Nout, R.A.; Van De Poll-Franse, L.V.; Lybeert, M.L.M.; Wárlám-Rodenhuis, C.C.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Pras, B.; Van Putten, W.L.J.; Creutzberg, C. Long-Term Outcome and Quality of Life of Patients With Endometrial Carcinoma Treated With or Without Pelvic Radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) Trial. J. Clin. Oncol. 2011, 29, 1692–1700. [Google Scholar] [CrossRef]
- de Boer, S.M.; E Powell, M.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): An open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016, 17, 1114–1126. [Google Scholar] [CrossRef] [Green Version]
- Keys, H.M.; Roberts, J.A.; Brunetto, V.L.; Zaino, R.J.; Spirtos, N.M.; Bloss, J.D.; Pearlman, A.; Maiman, M.A.; Bell, J.G. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol. Oncol. 2004, 92, 744–751. [Google Scholar] [CrossRef]
- Jhingran, A.; Winter, K.; Portelance, L.; Miller, B.; Salehpour, M.; Gaur, R.; Souhami, L.; Small, W.; Berk, L.; Gaffney, D. A Phase II Study of Intensity Modulated Radiation Therapy to the Pelvis for Postoperative Patients With Endometrial Carcinoma: Radiation Therapy Oncology Group Trial 0418. Int. J. Radiat. Oncol. 2012, 84, e23–e28. [Google Scholar] [CrossRef]
- Barillot, I.; Tavernier, E.; Peignaux, K.; Williaume, D.; Nickers, P.; Leblanc-Onfroy, M.; Lerouge, D. Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: Results of the phase II RTCMIENDOMETRE French multicentre trial. Radiother. Oncol. 2014, 111, 138–143. [Google Scholar] [CrossRef] [Green Version]
- Klopp, A.H.; Yeung, A.R.; Deshmukh, S.; Gil, K.M.; Wenzel, L.; Westin, S.N.; Gifford, K.; Gaffney, D.K.; Small, W.; Thompson, S.; et al. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology–RTOG 1203. J. Clin. Oncol. 2018, 36, 2538–2544. [Google Scholar] [CrossRef]
- Chopra, S.; Gupta, S.; Kannan, S.; Dora, T.; Engineer, R.; Mangaj, A.; Maheshwari, A.; Shylasree, T.S.; Ghosh, J.; Paul, S.N.; et al. Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial. J. Clin. Oncol. 2021, 39, 3682–3692. [Google Scholar] [CrossRef] [PubMed]
- Haie-Meder, C.; Pötter, R.; Van Limbergen, E.; Briot, E.; De Brabandere, M.; Dimopoulos, J.; Dumas, I.; Hellebust, T.P.; Kirisits, C.; Lang, S.; et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group☆ (I): Concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother. Oncol. 2005, 74, 235–245. [Google Scholar] [CrossRef] [PubMed]
- Escande, A.; Mazeron, R.; Gouy, S.; Bentivegna, E.; Maroun, P.; Fahra, G.; Oberlander, A.-S.; Dumas, I.; Castelnau-Marchand, P.; Deutsch, E.; et al. Preoperative image-guided brachytherapy in early stage cervical cancers. Radiother. Oncol. 2016, 120, 455–459. [Google Scholar] [CrossRef]
- Atlan, D.; Touboul, E.; Deniaud-Alexandre, E.; Lefranc, J.-P.; Antoine, J.-M.; Jannet, D.; Lhuillier, P.; Uzan, M.; Huart, J.; Genestie, C.; et al. Operable Stages IB and II cervical carcinomas: A retrospective study comparing preoperative uterovaginal brachytherapy and postoperative radiotherapy. Int. J. Radiat. Oncol. 2002, 54, 780–793. [Google Scholar] [CrossRef]
- Euscher, E.D.; Malpica, A.; Atkinson, E.N.; Levenback, C.F.; Frumovitz, M.; Deavers, M.T. Ultrastaging Improves Detection of Metastases in Sentinel Lymph Nodes of Uterine Cervix Squamous Cell Carcinoma. Am. J. Surg. Pathol. 2008, 32, 1336–1343. [Google Scholar] [CrossRef] [PubMed]
- Lentz, S.E.; Muderspach, L.I.; Felix, J.C.; Ye, W.; Groshen, S.; Amezcua, C.A. Identification of Micrometastases in Histologically Negative Lymph Nodes of Early-Stage Cervical Cancer Patients. Obstet. Gynecol. 2004, 103, 1204–1210. [Google Scholar] [CrossRef]
- Daraï, E.; Rouzier, R.; Ballester, M.; Barranger, E.; Coutant, C. Sentinel lymph node biopsy in gynaecological cancers: The importance of micrometastases in cervical cancer. Surg. Oncol. 2008, 17, 227–235. [Google Scholar] [CrossRef]
- Cibula, D.; Abu-Rustum, N.R.; Dušek, L.; Zikan, M.; Zaal, A.; Sevcik, L.; Kenter, G.G.; Querleu, D.; Jach, R.; Bats, A.-S.; et al. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol. Oncol. 2012, 124, 496–501. [Google Scholar] [CrossRef]
- Guani, B.; Dorez, M.; Magaud, L.; Buenerd, A.; Lecuru, F.; Mathevet, P. Impact of micrometastasis or isolated tumor cells on recurrence and survival in patients with early cervical cancer: SENTICOL Trial. Int. J. Gynecol. Cancer 2019, 29, 447–452. [Google Scholar] [CrossRef]
- Sehouli, J.; Runnebaum, I.B.; Fotopoulou, C.; Blohmer, U.; Belau, A.; Leber, H.; Hanker, L.C.; Hartmann, W.; Richter, R.; Keyver-Paik, M.D.; et al. A randomized phase III adjuvant study in high-risk cervical cancer: Simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A NOGGO-AGO Intergroup Study. Ann. Oncol. 2012, 23, 2259–2264. [Google Scholar] [CrossRef]
- Huang, H.; Feng, Y.L.; Wan, T.; Zhang, Y.N.; Cao, X.P.; Huang, Y.W.; Xiong, Y.; Huang, X.; Zheng, M.; Li, Y.F.; et al. Effectiveness of Sequential Chemoradiation vs. Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021, 7, 361–369. [Google Scholar] [CrossRef] [PubMed]
- Whitney, C.W.; Sause, W.; Bundy, B.N.; Malfetano, J.H.; Hannigan, E.V.; Fowler, W.C., Jr.; Clarke-Pearson, D.L.; Liao, S.-Y. Randomized Comparison of Fluorouracil Plus Cisplatin Versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix With Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study. J. Clin. Oncol. 1999, 17, 1339. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rose, P.G.; Bundy, B.N.; Watkins, E.B.; Thigpen, J.T.; Deppe, G.; Maiman, M.A.; Clarke-Pearson, D.L.; Insalaco, S. Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer. N. Engl. J. Med. 1999, 340, 1144–1153. [Google Scholar] [CrossRef] [PubMed]
- Morris, M.; Eifel, P.J.; Lu, J.; Grigsby, P.W.; Levenback, C.; Stevens, R.E.; Rotman, M.; Gershenson, D.M.; Mutch, D.G. Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer. N. Engl. J. Med. 1999, 340, 1137–1143. [Google Scholar] [CrossRef]
- Keys, H.M.; Bundy, B.N.; Stehman, F.B.; Muderspach, L.I.; Chafe, W.E.; Suggs, C.L., 3rd; Walker, J.L.; Gersell, D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 1999, 340, 1154–1161. [Google Scholar] [CrossRef]
- Chargari, C.; Deutsch, E.; Blanchard, P.; Gouy, S.; Martelli, H.; Guérin, F.; Dumas, I.; Bossi, A.; Morice, P.; Viswanathan, A.N.; et al. Brachytherapy: An overview for clinicians. CA A Cancer J. Clin. 2019, 69, 386–401. [Google Scholar] [CrossRef] [Green Version]
- Escande, A.; Khettab, M.; Bockel, S.; Dumas, I.; Schernberg, A.; Gouy, S.; Morice, P.; Pautier, P.; Deutsch, E.; Haie-Meder, C.; et al. Interaction between the Number of Chemotherapy Cycles and Brachytherapy Dose/Volume Parameters in Locally Advanced Cervical Cancer Patients. J. Clin. Med. 2020, 9, 1653. [Google Scholar] [CrossRef]
- Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized trials. J. Clin. Oncol. 2008, 26, 5802–5812. [Google Scholar] [CrossRef] [Green Version]
- Pötter, R.; Tanderup, K.; Kirisits, C.; De Leeuw, A.; Kirchheiner, K.; Nout, R.; Tan, L.T.; Haie-Meder, C.; Mahantshetty, U.; Segedin, B.; et al. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin. Transl. Radiat. Oncol. 2018, 9, 48–60. [Google Scholar] [CrossRef] [Green Version]
- Querleu, D.; Dargent, D.; Ansquer, Y.; Leblanc, E.; Narducci, F. Extraperitoneal endosurgical aortic and common iliac dissection in the staging of bulky or advanced cervical carcinomas. Cancer 2000, 88, 1883–1891. [Google Scholar] [CrossRef]
- Rafii, A.; Camicas, A.; Ferron, G.; Mery, E.; Gladieff, L.; Delannes, M.; Querleu, D. A comparative study of laparoscopic extraperitoneal lymphadenectomy [correction of laparoscopy] with the use of ultrasonically activated shears. Am. J. Obstet. Gynecol. 2009, 201, 370.e1. [Google Scholar] [CrossRef] [PubMed]
- Morice, P.; Castaigne, D.; Pautier, P.; Rey, A.; Haie-Meder, C.; Leblanc, M.; Duvillard, P. Interest of Pelvic and Paraaortic Lymphadenectomy in Patients with Stage IB and II Cervical Carcinoma. Gynecol. Oncol. 1999, 73, 106–110. [Google Scholar] [CrossRef] [PubMed]
- Kidd, E.A.; Siegel, B.A.; Dehdashti, F.; Rader, J.S.; Mutch, D.G.; Powell, M.A.; Grigsby, P.W. Lymph Node Staging by Positron Emission Tomography in Cervical Cancer: Relationship to Prognosis. J. Clin. Oncol. 2010, 28, 2108–2113. [Google Scholar] [CrossRef] [PubMed]
- Gouy, S.; Morice, P.; Narducci, F.; Uzan, C.; Gilmore, J.; Kolesnikov-Gauthier, H.; Querleu, D.; Haie-Meder, C.; Leblanc, E. Nodal-staging surgery for locally advanced cervical cancer in the era of PET. Lancet Oncol. 2012, 13, e212–e220. [Google Scholar] [CrossRef]
- Jamal, D.N.; Pötter, R.; Haie-Meder, C.; Lindegaard, J.C.; Juergenliemk-Schulz, I.M.; Mahantshetty, U.; Segedin, B.; Bruheim, K.; Hoskin, P.; Rai, B.; et al. Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: A report from the EMBRACE study. Radiother. Oncol. 2018, 127, 449–455. [Google Scholar] [CrossRef]
- Pötter, R.; Dimopoulos, J.; Georg, P.; Lang, S.; Waldhäusl, C.; Wachter-Gerstner, N.; Weitmann, H.; Reinthaller, A.; Knocke, T.H.; Wachter, S.; et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother. Oncol. 2007, 83, 148–155. [Google Scholar] [CrossRef]
- Dimopoulos, J.C.; Potter, R.; Lang, S.; Fidarova, E.; Georg, P.; Dorr, W.; Kirisits, C. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy . Radiother. Oncol. 2009, 93, 311–315. [Google Scholar] [CrossRef]
- Chargari, C.; Magné, N.; Dumas, I.; Messai, T.; Vicenzi, L.; Gillion, N.; Morice, P.; Haie-Meder, C. Physics Contributions and Clinical Outcome With 3D-MRI–Based Pulsed-Dose-Rate Intracavitary Brachytherapy in Cervical Cancer Patients. Int. J. Radiat. Oncol. 2009, 74, 133–139. [Google Scholar] [CrossRef]
- Mazeron, R.; Castelnau-Marchand, P.; Dumas, I.; del Campo, E.R.; Kom, L.K.; Martinetti, F.; Farha, G.; Tailleur, A.; Morice, P.; Chargari, C.; et al. Impact of treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemoradiation and image-guided pulsed-dose rate adaptive brachytherapy. Radiother. Oncol. 2015, 114, 257–263. [Google Scholar] [CrossRef]
- Lindegaard, J.C.; Fokdal, L.U.; Nielsen, S.K.; Juul-Christensen, J.; Tanderup, K. MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncol. 2013, 52, 1510–1519. [Google Scholar] [CrossRef] [Green Version]
- Charra-Brunaud, C.; Harter, V.; Delannes, M.; Haie-Meder, C.; Quetin, P.; Kerr, C.; Castelain, B.; Thomas, L.; Peiffert, D. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: Results of the French STIC prospective study. Radiother. Oncol. 2012, 103, 305–313. [Google Scholar] [CrossRef] [PubMed]
- Tanderup, K.; Fokdal, L.U.; Sturdza, A.; Haie-Meder, C.; Mazeron, R.; van Limbergen, E.; Jürgenliemk-Schulz, I.; Petric, P.; Hoskin, P.; Doerr, W.; et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother. Oncol. 2016, 120, 441–446. [Google Scholar] [CrossRef] [PubMed]
- Girinsky, T.; Rey, A.; Roche, B.; Haie, C.; Gerbaulet, A.; Randrianarivello, H.; Chassagne, D. Overall treatment time in advanced cervical carcinomas: A critical parameter in treatment outcome. Int. J. Radiat. Oncol. 1993, 27, 1051–1056. [Google Scholar] [CrossRef]
- Perez, C.A. Changing patterns of care in carcinoma of the uterine cervix: Need for cost-benefit studies. Int. J. Radiat. Oncol. 1995, 32, 1535–1537. [Google Scholar] [CrossRef]
- Morice, P.; Uzan, C.; Zafrani, Y.; Delpech, Y.; Gouy, S.; Haie-Meder, C. The role of surgery after chemoradiation therapy and brachytherapy for stage IB2/II cervical cancer. Gynecol. Oncol. 2007, 107 (Suppl. 1), S122–S124. [Google Scholar] [CrossRef]
- Keys, H.M.; Bundy, B.N.; Stehman, F.B.; Okagaki, T.; Gallup, D.G.; Burnett, A.F.; Rotman, M.Z.; Fowler, W.C., Jr. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: A randomized trial of the Gynecologic Oncology Group. Gynecol. Oncol. 2003, 89, 343–353. [Google Scholar] [CrossRef]
- Cetina, L.; González-Enciso, A.; Cantú, D.; Coronel, J.; Pérez-Montiel, D.; Hinojosa, J.; Serrano, A.; Rivera, L.; Poitevin, A.; Mota, A.; et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: A randomized, phase III study in IB2–IIB cervical cancer patients. Ann. Oncol. 2013, 24, 2043–2047. [Google Scholar] [CrossRef]
- Mazeron, R.; Gouy, S.; Chargari, C.; del Campo, E.R.; Dumas, I.; Mervoyer, A.; Genestie, C.; Bentivegna, E.; Balleyguier, C.; Pautier, P.; et al. Post radiation hysterectomy in locally advanced cervical cancer: Outcomes and dosimetric impact. Radiother. Oncol. 2016, 120, 460–466. [Google Scholar] [CrossRef]
- Gosset, M.; Chargari, C.; Bentivegna, E.; Leary, A.; Genestie, C.; Maulard, A.; Morice, P.; Gouy, S. Should We Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer? Anticancer Res. 2019, 39, 2919–2926. [Google Scholar] [CrossRef] [Green Version]
- Azria, E.; Morice, P.; Haie-Meder, C.; Thoury, A.; Pautier, P.; Lhomme, C.; Duvillard, P.; Castaigne, D. Results of hysterectomy in patients with bulky residual disease at the end of chemoradiotherapy for stage IB2/II cervical carcinoma. Ann. Surg. Oncol. 2005, 12, 332–337. [Google Scholar] [CrossRef]
- Mignot, F.; Gouy, S.; Schernberg, A.; Bockel, S.; Espenel, S.; Maulard, A.; Leary, A.; Genestie, C.; Annede, P.; Kissel, M.; et al. Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy. Gynecol. Oncol. 2020, 157, 644–648. [Google Scholar] [CrossRef]
- Marnitz, S.; Köhler, C.; Müller, M.; Behrens, K.; Hasenbein, K.; Schneider, A. Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol. Oncol. 2006, 103, 1023–1030. [Google Scholar] [CrossRef] [PubMed]
- Martinez, A.; Filleron, T.; Rouanet, P.; Meeus, P.; Lambaudie, E.; Classe, J.M.; Foucher, F.; Narducci, F.; Gouy, S.; Guyon, F.; et al. Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study. Ann. Surg. Oncol. 2018, 25, 535–541. [Google Scholar] [CrossRef] [PubMed]
- Tewari, K.S.; Sill, M.W.; Long, H.J., 3rd; Penson, R.T.; Huang, H.; Ramondetta, L.M.; Landrum, L.M.; Oaknin, A.; Reid, T.J.; Leitao, M.M.; et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. N. Engl. J. Med. 2017, 377, 702. [Google Scholar]
- Gupta, S.; Maheshwari, A.; Parab, P.; Mahantshetty, U.; Hawaldar, R.; Sastri Chopra, S.; Kerkar, R.; Engineer, R.; Tongaonkar, H.; Ghosh, J.; et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: A randomized controlled trial. J. Clin. Oncol. 2018, 36, 1548–1555. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kenter, G.; Greggi, S.; Vergote, I.; Katsaros, D.; Kobierski, J.; Massuger, L.; Van Doorn, H.C.; Landoni, F.; Van Der Velden, J.; Reed, N.S.; et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994. J. Clin. Oncol. 2019, 37 (Suppl. 15), 5503. [Google Scholar] [CrossRef]
- Da Costa, S.C.S.; Bonadio, R.C.; Gabrielli, F.C.G.; Aranha, A.S.; Dias Genta, M.L.; Miranda, V.C.; De Freitas, D.; Abdo Filho, E.; Ferreira, P.A.O.; Machado, K.K.; et al. Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial. J. Clin. Oncol. 2019, 37, 3124–3131. [Google Scholar] [CrossRef]
- McCormack, M.; Kadalayil, L.; Hackshaw, A.; Hall-Craggs, M.; Symonds, R.P.; Warwick, V.; Simonds, H.; Fernando, I.; Hammond, M.; James, L.; et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br. J. Cancer 2013, 108, 2464–2469. [Google Scholar] [CrossRef]
- Sturdza, A.; Pötter, R.; Fokdal, L.U.; Haie-Meder, C.; Tan, L.T.; Mazeron, R.; Petric, P.; Šegedin, B.; Jurgenliemk-Schulz, I.M.; Nomden, C.; et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother. Oncol. 2016, 120, 428–433. [Google Scholar] [CrossRef]
- Dueñas-González, A.; Zarbá, J.J.; Patel, F.; Alcedo, J.C.; Beslija, S.; Casanova, L.; Pattaranutaporn, P.; Hameed, S.; Blair, J.M.; Barraclough, H.; et al. Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix. J. Clin. Oncol. 2011, 29, 1678–1685. [Google Scholar] [CrossRef]
- Mileshkin, L.R.; Moore, K.N.; Barnes, E.; Gebski, V.; Narayan, K.; Bradshaw, N.; Lee, Y.C.; Diamante, K.; Fyles, A.W.; Small, W.; et al. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274). J. Clin. Oncol. 2021, 39 (Suppl. 18), LBA3. [Google Scholar] [CrossRef]
- Colombo, N.; Dubot, C.; Lorusso, D.; Caceres, M.V.; Hasegawa, K.; Shapira-Frommer, R.; Tewari, K.S.; Salman, P.; Usta, E.H.; Yanez, E.; et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N. Engl. J. Med. 2021, 385, 1856–1867. [Google Scholar] [CrossRef] [PubMed]
- Migden, M.R.; Rischin, D.; Schmults, C.D.; Guminski, A.; Hauschild, A.; Lewis, K.D.; Chung, C.H.; Hernandez-Aya, L.F.; Lim, A.M.; Chang, A.L.S.; et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N. Engl. J. Med. 2018, 379, 341–351. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Migden, M.R.; Khushalani, N.I.; Chang, A.L.S.; Lewis, K.D.; Schmults, C.D.; Hernandez-Aya, L.; Meier, F.; Schadendorf, D.; Guminski, A.; Hauschild, A.; et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020, 21, 294–305. [Google Scholar] [CrossRef]
- Sezer, A.; Kilickap, S.; Gümüş, M.; Bondarenko, I.; Özgüroğlu, M.; Gogishvili, M.; Turk, H.M.; Cicin, I.; Bentsion, D.; Gladkov, O.; et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 2021, 397, 592–604. [Google Scholar] [CrossRef]
- Rischin, D.; Gil-Martin, M.; González-Martin, A.; Braña, I.; Hou, J.Y.; Cho, D.; Falchook, G.S.; Formenti, S.; Jabbour, S.; Moore, K.; et al. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecol. Oncol. 2020, 159, 322–328. [Google Scholar] [CrossRef] [PubMed]
- Mayadev, J.; Nunes, A.T.; Li, M.; Marcovitz, M.; Lanasa, M.C.; Monk, B.J. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: A phase III, randomized, double-blind, multicenter study. Int. J. Gynecol. Cancer 2020, 30, 1065–1070. [Google Scholar] [CrossRef]
- Mayadev, J.; Zamarin, D.; Deng, W.; Lankes, H.; O’Cearbhaill, R.; Aghajanian, C.A.; Schilder, R. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. Int. J. Gynecol. Cancer 2019, 30, 701–704. [Google Scholar] [CrossRef]
- Huang, X.; He, M.; Peng, H.; Tong, C.; Liu, Z.; Zhang, X.; Shao, Y.; Zhu, D.; Zhang, J.; Yin, J.C.; et al. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: A secondary analysis of the CLAP trial. J. Immunother. Cancer 2021, 9, e002223. [Google Scholar] [CrossRef]
- Reuzé, S.; Orlhac, F.; Chargari, C.; Nioche, C.; Limkin, E.; Riet, F.; Escande, A.; Haie-Meder, C.; Dercle, L.; Gouy, S.; et al. Prediction of cervical cancer recurrence using textural features extracted from 18F-FDG PET images acquired with different scanners. Oncotarget 2017, 8, 43169–43179. [Google Scholar] [CrossRef] [Green Version]
- Schernberg, A.; Bockel, S.; Annede, P.; Fumagalli, I.; Escande, A.; Mignot, F.; Kissel, M.; Morice, P.; Bentivegna, E.; Gouy, S.; et al. Tumor Shrinkage During Chemoradiation in Locally Advanced Cervical Cancer Patients: Prognostic Significance, and Impact for Image-Guided Adaptive Brachytherapy. Int. J. Radiat. Oncol. 2018, 102, 362–372. [Google Scholar] [CrossRef] [PubMed]
- Takeuchi, S.; Kagabu, M.; Shoji, T.; Nitta, Y.; Sugiyama, T.; Sato, J.; Nakamura, Y. Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]. OncoImmunology 2020, 9, 1838189. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zhou, Y.; Rassy, E.; Coutte, A.; Achkar, S.; Espenel, S.; Genestie, C.; Pautier, P.; Morice, P.; Gouy, S.; Chargari, C. Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies. Cancers 2022, 14, 2449. https://doi.org/10.3390/cancers14102449
Zhou Y, Rassy E, Coutte A, Achkar S, Espenel S, Genestie C, Pautier P, Morice P, Gouy S, Chargari C. Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies. Cancers. 2022; 14(10):2449. https://doi.org/10.3390/cancers14102449
Chicago/Turabian StyleZhou, Yuedan, Elie Rassy, Alexandre Coutte, Samir Achkar, Sophie Espenel, Catherine Genestie, Patricia Pautier, Philippe Morice, Sébastien Gouy, and Cyrus Chargari. 2022. "Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies" Cancers 14, no. 10: 2449. https://doi.org/10.3390/cancers14102449